1-(4-氨基丁基)吡咯烷-2,5-二酮 | 90289-33-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(4-氨基丁基)吡咯烷-2,5-二酮
• 英文名称: N-(4-amino-butyl)-succinimide
• 英文别名: N-(4-Amino-butyl)-succinimid；1-(4-Aminobutyl)pyrrolidine-2,5-dione
• CAS: 90289-33-1
• 化学式: C₈H₁₄N₂O₂
• 分子量: 170.211
• InChiKey: XRGHGHOLFBMYAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  丁二酰亚胺 在 1,4-二氧六环 、 chromium(III) oxide 、 copper(II) oxide 作用下， 250.0 ℃ 、29.42 MPa 条件下， 生成 1-(4-氨基丁基)吡咯烷-2,5-二酮 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Catalytic Hydrogenation of Amides to Amines

  摘要：

  DOI：

  10.1021/ja01326a061

文献信息

• DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS
  申请人：Universidade de Santiago de Compostela

  公开号：EP3703666A1

  公开（公告）日：2020-09-09
• INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES
  申请人：Universidade de Santiago de Compostela

  公开号：US20220177603A1

  公开（公告）日：2022-06-09

  Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.
• [EN] INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES<br/>[FR] ADMINISTRATION INTRACELLULAIRE D'ANTICORPS ANTI-KRAS FORMULÉS DANS DES NANOCAPSULES
  申请人：UNIV SANTIAGO COMPOSTELA

  公开号：WO2020221849A1

  公开（公告）日：2020-11-05

  Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.
• Catalytic Hydrogenation of Amides to Amines
  作者：Bruno Wojcik、Homer Adkins

  DOI：10.1021/ja01326a061

  日期：1934.11